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OBJECTIVE: The aim of this study was to summarize the experience of a tertiary center in treating
hepatoblastoma for the last 21 years.
PATIENTS AND METHODS: Fifty-eight cases were included. The tumor extent and prognosis were assessed using
the PRETEXT system. The following data were analyzed: age at diagnosis, comorbidities, prematurity, treatment
modalities, histopathological findings, surgical details and complications, treatment outcomes, chemotherapy
schedules, side effects and complications. Treatment outcomes included the occurrence of local or distant
recurrence, the duration of survival and the cause of death. The investigation methods were ultrasonography,
CT scan, serum alpha-fetoprotein level measurement and needle biopsy. Chemotherapy was then planned, and
the resectability of the tumor was reevaluated via another CT scan.
RESULTS: The mean numbers of neoadjuvant cycles and postoperative cycles of chemotherapy were 6±2 and
1.5±1.7, respectively. All children except one were submitted for surgical resection, including 50 partial liver
resections and 7 liver transplantations. Statistical comparisons demonstrated that long-term survival was
associated with the absence of metastasis (p=0.04) and the type of surgery (resection resulted in a better
outcome than transplantation) (p=0.009). No associations were found between vascular invasion, incomplete
resection, histological subtype, multicentricity and survival. The overall 5-year survival rate of the operated cases
was 87.7%.
CONCLUSION: In conclusion, the experience of a Brazilian tertiary center in the management of
hepatoblastoma in children demonstrates that long survival is associated with the absence of metastasis and
the type of surgery. A multidisciplinary treatment involving chemotherapy, surgical resection and liver
transplantation (including transplantations using tissue from living donors) led to good outcomes and survival
indexes.
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’ INTRODUCTION
Hepatoblastoma is the most common malignant liver
tumor in children; it accounts for 50% of liver tumors and
1.3% of malignant tumors in children (1). Hepatoblastoma is
generally sensitive to chemotherapy. Surgery combined with
chemotherapy can significantly improve the remission rate,
which is as high as 70% (2).
The recommended timing of chemotherapy varies. The
evolution of chemotherapeutic agents, predominantly cispla-
tin-based treatments used in neoadjuvant and adjuvant proto-
cols, has largely contributed to the decrease in mortality among
hepatoblastoma patients over the past several decades (3,4,5).
However, surgical resection remains the cornerstone of
curative treatment in all age groups with hepatoblastoma.
Surgical resection to achieve extirpation of a hepatoblastoma
includes segmentectomy, sectionectomy, and/or hemihepa-
tectomy for PRETEXT I and II tumors and trisectionectomy
for PRETEXT III and IV tumors. Recently, liver transplanta-
tion has been performed for unresectable disease (bilobar
portal vein or hepatic vein and inferior vena cava invasion,DOI: 10.6061/clinics/2015(06)01
Copyright & 2015 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial
use, distribution, and reproduction in any medium, provided the original work is
properly cited.
No potential conflict of interest was reported.
387
CLINICAL SCIENCE
as well as extensive loss of normal parenchyma) in cases with
no evidence of distant metastasis (6,7).
In this study, we aimed to summarize our experience in
treating hepatoblastoma for the last 21 years. We then
analyzed the clinical therapeutic effects, complications and
outcomes of chemotherapy, surgery, and liver transplanta-
tion as administered to these patients.
’ PATIENTS AND METHODS
The medical records of children admitted to our institution
with a diagnosis of hepatoblastoma between January 1993
and January 2014 were reviewed. A total of 58 cases were
included in this study. All diagnoses were confirmed
by histological examination. Children were prospectively
followed based on periodic outpatient reviews.
For all patients, the tumor extent and prognosis were
assessed using the PRETreatment EXTent of disease
(PRETEXT) system. The following data were analyzed:
age at diagnosis, comorbidities, prematurity, treatment
modalities, histopathological findings, surgical details,
operative complications, and treatment outcomes. Che-
motherapy schedules, side effects, complications and
outcomes were evaluated.
The collected data related to surgery included the extent of
hepatic resection, the presence or absence of free margins,
and the occurrence of operative complications.
If the tumor was considered to be unresectable according
to the results of the postchemotherapy CT scan, liver
transplantation was considered. Before transplantation was
approved, the patient underwent extensive scanning to
search for distant metastases.
Treatment outcomes were evaluated according to the
occurrence of local or distant recurrence, the duration of
survival, and the cause of death.
Investigation methods
Ultrasonography was the first imaging tool used in all
patients clinically suspected to have an abdominal mass.
Once the presence of a liver tumor was confirmed by
ultrasonography, a CT scan was performed to evaluate the
extent of the lesion, its vascular supply, the involvement of
adjacent organs and lymph nodes, and the relationship of the
mass to major vessels such as the portal vein, hepatic
arteries, and hepatic veins.
After monitoring the initial alpha-fetoprotein level, a
needle biopsy was performed to histologically diagnose the
tumor. Biopsies were echo-guided and were resected through
the adjacent normal parenchyma to avoid spillage into the
peritoneum. Neoadjuvant chemotherapy was planned. The
impact of chemotherapy and the resectability of the tumor
were evaluated via another CT scan.
Standard clinical staging
According to the International Society of Pediatric Oncol-
ogy (SIOP) (8), pre-operative hepatoblastoma (PRETEXT) is
divided into four stages, ranging from stage I to stage IV.
Treatment programs
In most cases, the chemotherapy schedules included
cisplatin and doxorubicin. Four patients received cisplatin
plus etoposide, four received only cisplatin, and five received
cisplatin plus carboplatin plus doxorubicin. The mean
number of chemotherapy courses before surgery was five.
Except for one case in which the histological assessment
revealed 100% necrotic cells in the liver tumor, all patients
also received postoperative chemotherapy.
Surgical treatment
Liver resection. A bilateral subcostal incision was
preferred, as it enabled good exposure of the operative field
and an acceptable cosmetic appearance. As tumor extension
was carefully assessed preoperatively via a CT scan
performed a few days before the surgery, intraoperative
ultrasound was not performed.
The liver was fully mobilized by detaching all anterior
and posterior ligamentous attachments to the abdominal
wall and to the diaphragm. The liver was then reflected
upward to expose the inferior surface and enable hilar
structure identification. The extent of the tumor and the
possibility of resection could then be assessed. The anatomi-
cal site, extension, and vascular involvement of the tumor
were carefully analyzed, and the abdomen was thoroughly
examined for the presence of any metastases. After the type
of resection was determined, the related vascular and biliary
structures were identified and isolated.
As lymph node extension is very rare in cases of
hepatoblastoma, hilar structures and arterial and portal
venous branches were dissected close to the parenchyma to
avoid hilar vessel lesions on the other side of the organ.
In most cases, the biliary duct was transected and ligated
during parenchymal sectioning. The suprahepatic inferior
vena cava was exposed to enable easy control of hemorrha-
ging, if necessary. The hepatic veins were identified, and the
right, middle, or left hepatic vein was isolated and secured
depending on the type and the extent of resection. In cases of
right hepatectomy, all of the small branches arising from the
right lobe to the inferior vena cava were ligated and
sectioned. During this dissection, the venous infusion was
decreased by the anesthetic team to reduce central venous
pressure and potential bleeding from the hepatic veins and
the vena cava. Parenchymal division near the hilar region
was directed toward the lobe that would be removed,
thereby avoiding common bile duct lesions.
The parenchymal transection was performed using the
Cavitron ultrasonic aspirator (CUSA, Valley Lab, Boulder,
CO) or a LigaSure electrocautery held by the surgeon and a
bipolar electrocautery held by the first assistant. Peritoneal
drainage was routinely performed using a Jackson-Pratts
drain near the raw surface of the liver.
Liver transplantation. In 7 cases, living related donor
liver transplantation was performed. In contrast to liver
transplantations for benign diseases, the procedure began
with the recipient laparotomy and a comprehensive analysis
of tumor extension and peritoneal or other abdominal organ
involvement. The donor procedure was then initiated.
All of the donors were operated on by the same team of
pediatric surgeons, and the recipient procedures were
performed by one surgeon. The donor and recipient
procedures were simultaneously performed in the university
pediatric hospital in two connected operating rooms that
were specifically adapted for these procedures.
In two cases, the liver grafts were procured from adult
cadaveric donors. A graft reduction was performed with
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preservation of the left lateral segment, which was implanted
into the recipient.
Statistical analysis
Multiple statistical comparisons were performed using
binary logistic regression analyses, and Fisher’s exact test
was used with the aid of Statistical Package for Social
Sciences (SPSS) for Windows, version 15.0. The following
variables were analyzed: the presence of metastasis at the
time of diagnosis, the type of resection (complete or
incomplete), the presence of vascular invasion, multicentri-
city, the type of surgical treatment (resection or transplanta-
tion), histopathological findings, and the PRETEXT stage.
These variables were compared with the final survival
outcome to test for significance.
’ RESULTS
The baseline characteristics of the patients at diagnosis are
summarized in Table 1. Considering patients within the last
5 years (2009 to 2014), 25% were premature at birth. In the
previous period, prematurity occurred in only 5% of cases.
Primary tumor data such as histology, PRETEXT stage,
multifocality, vascular involvement and the presence of
metastasis at diagnosis are presented in Table 2.
The mean numbers of neoadjuvant cycles and post-
operative cycles of chemotherapy were 6±2 and was
1.5±1.7, respectively. A total of 10% of the patients required
hospitalization for febrile neutropenia, and 3.4% presented
with cardiac dysfunction that was controlled clinically or
with medications. However, no deaths related to chemother-
apy complications occurred.
Surgical resections included 19 right hepatectomies,
12 right trisectionectomies, 11 left hepatectomies, 3 mono-
segment (segment IV a and b) resections, 3 left trisectio-
nectomies and 2 left segmentectomies. Seven children
underwent liver transplantation: 4 surgeries were primary
transplants, and 3 were rescue transplants after liver
recurrence. One child was not submitted to surgical
treatment due to the presence of peritoneal carcinomatosis
and an unresectable tumor.
The following postoperative complications occurred in 8
children (13.8%): biliary leakage on the cut surface (2), bowel
subocclusion (2), early postoperative bleeding (1), surgical
infection (1), and transitory hypoglycemia (1). Repeated
operations were necessary in 3 cases (5.17%) because of
biliary leakage, early intestinal adhesions, and hemorrhage.
Free microscopic margins were obtained in 45 of the 50
patients submitted for surgical resections. In 3 children
(including 2 incomplete resection cases), the disease recurred
locally, and one of these children also had distant metastasis.
The main data related to surgical resections are shown in
Table 3. One early death due to sepsis occurred after a left
trisectionectomy. Among the children submitted to liver
transplantation, 4 of them remain alive with no disease
recurrence. The other 3 died due to tumor relapse; all of them
relapsed during the first year after left trisectionectomy. The
overall survival rate of the operated cases was 87.7%, and
85.7% of postoperative deaths were related to the recurrence
of malignant disease (all cases were PRETEXT IV tumors).
The median follow-up duration was 2.3 years (range,
6 months-23 years).
The statistical comparisons using Fisher’s exact test
revealed a strong association between the absence of
metastasis and survival (p=0.04). A correlation was also
observed between the type of surgery (resection compared
with transplantation) and survival (p=0.009). No significant
associations were found between vascular invasion, incom-
plete resection, histological subtype, multicentricity and
survival. As the total number of deaths was relatively low,
no significant associations were observed based on logistic
regression analyses.
’ DISCUSSION
Most liver tumors in children are metastatic lesions of
neuroblastoma, Wilms’ tumor or lymphoma, and the
incidence of primary liver tumors in children is low (9,10).
Table 1 - Main patient characteristics at the time of
hepatoblastoma diagnosis.
Variable Median or number Percent or range
Gender
Male 30 51.7
Female 28 48.3
Age 1 y 10 ms 2 ms–12 ys
Prematurity 11 18.9
Table 2 - Tumor characteristics.
Number of patients (%)
Histological subtype (main component)
Epithelial fetal 17 (29.3)
Epithelial embryonal 7 (12.1)
Mixed epithelial and mesenchymal with
teratoid features
9 (15.5)
Mixed epithelial and mesenchymal
without teratoid features
24 (41.4)
Small cell undifferentiated (SCUD) 1 (1.7)
PRETEXT stage
I 2 (3.4)
II 12 (20.6)
III 27 (46.6)
IV 17 (29.3)
Tumor focality
Unifocal 51 (88)
Multifocal 7 (12)
Vascular involvement (microscopic
or macroscopic)
16 (27.6)
Metastasis 5 (8.6)
Table 3 - Main results of children submitted for surgical
resection of hepatoblastoma.
Surgical resections 19 right hepatectomies
12 right trisectionectomies
11 left hepatectomies
3 monosegment (segment IV a and IVb)
resections
3 left trisectionectomies
2 left segmentectomies
Postoperative complications 2 biliary leakage on cut surface
2 bowel subocclusion
1 early postoperative bleeding
1 surgical infection
1 transitory hypoglycemia
Free microscopic margins 45
Reoperations 3
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Thus, it takes many years for a pediatric surgeon to gain
enough experience to properly perform a hepatic resection.
The current series of patients was treated in a major
university reference center staffed by an experienced group
of pediatric clinical oncologists and pediatric surgeons with
expertise in surgical oncology and pediatric liver transplan-
tation. All of these accumulated experiences were respon-
sible for the good outcomes reported herein.
The approach to the investigation and treatment of
hepatoblastoma in children has evolved in the last 20 years;
at present, children with this disease are diagnosed and
treated with chemotherapy and surgery according to
universally established protocols. This standardization has
resulted in excellent survival rates of 70%-85% according to
various reports (11,12). In addition to the chemotherapy
protocols, refinements in the surgical techniques for liver
resections and adequate immediate postoperative treatment
in pediatric intensive care units have contributed to this
progress.
For proper diagnosis, we utilized an investigation protocol
that is in accordance with the recommendations in the
literature for the treatment of liver tumors. An initial
ultrasound examination followed by a CT scan provides
useful information about the nature of the tumor. In all cases,
a diagnosis of suspected hepatoblastoma was confirmed by a
needle biopsy, which additionally revealed the pathological
type of the tumor. No complications related to biopsies
occurred.
All cases in the present series were submitted to cycles of
chemotherapy prior to surgical resection. This timing is
important because chemotherapy reduces the tumor volume
and because there is a strong correlation between a good
response to chemotherapy and a higher survival rate, despite
the presence of more advanced disease (13). We have
observed that previous chemotherapy enables resectability
in cases of tumors that were previously considered to be
unresectable. Despite the need for hospitalization due to
chemotherapy (primarily due to febrile neutropenia) in some
cases, the morbidity was relatively low, and the survival
benefits are incontestable.
Interestingly, prematurity and low birth weight have been
associated with an increased risk of hepatoblastoma (14,15,16).
In fact, we found a high percentage of a history of
prematurity in our patients, and this percentage has
increased in recent years (25%). A case-control study
developed by the Childreń s Oncology Group aimed to
elucidate the reasons for these associations (17). Children
diagnosed with hepatoblastoma had a significantly longer
exposure to respiratory support, greater exposure to anti-
biotics and more radiographic exams than controls.
Although other studies demonstrated increased risk for
hepatoblastoma among children with low or very low birth
Figure 1 - Surgical aspect of a patient with multifocal hepatoblastoma. Note the multiple nodes affecting all of the liver parenchyma
(PRETEX IV). The patient underwent total hepatectomy and living donor liver transplantation.
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weight, with preterm birth o33 weeks, with small size for
gestational age, and from multiple birth pregnancies (17), the
actual explanation for these observations remains unknown.
The present study showed a low surgical complication rate
and satisfactory treatment outcomes. To obtain this excellent
result, we utilized certain surgical techniques that were
learned from our extensive experience with liver transplan-
tation surgeries (9). Surgical refinements of all steps of this
complex procedure (including donor - living or cadaveric -
hepatectomy, back-table surgery, recipient hepatectomy and
graft implant techniques) may be applied to all liver
surgeries, especially hepatic resections for neoplastic lesions.
Similar to the conditions of recipient resection of the native
liver, in situations of liver transplantation during a surgery
for hepatoblastoma resection, the hilar structures of the
hepatic lobe to be resected are dissected very close to
the parenchyma to avoid injury to any vessels of the other
lobe. By following this principle, we did not have any
complications related to damage to the vasculature of the
remaining lobe.
Regarding the type of resection, 45 cases had free
microscopic margins. Fortunately, with the current use of
adequate adjuvant chemotherapy, potential microscopic
residues or microscopically incomplete resection do not
negatively impact survival (18,19). However, a wide margin
of normal parenchyma lacking tumor cells does not prevent
recurrence in cases of poor histological prognosis (20). Our
policy was to maintain the resection line far from the tumor
whenever possible, although in some cases, we had to
perform the resection very close to the tumor to avoid
damage to the remaining liver lobe.
The influence of histological subtype on hepatoblastoma
prognosis remains unclear. In contrast to other publications
that reported that the epithelial subtype was the most
frequent (21,22), in our case series, mixed epithelial and
mesenchymal hepatoblastoma without teratoid features
represented 41.4% of all cases. Pure fetal histology was
thought to be associated with a better prognosis (23). In fact,
it has been advocated that complete surgical resection is
curative for children with hepatoblastoma with a pure fetal
histology and that chemotherapy should be minimized in
these cases (24). However, the small cell undifferentiated
histological subtype has been associated with reduced
patient survival (24,25). However, in our case series, there
was no association between the histopathological findings
and prognosis. The relatively small number of cases of each
histological subtype may have limited the statistical analysis;
thus, more comprehensive studies, such as nationwide
retrospective or cooperative studies with pediatric oncology
groups, would lead to more meaningful results.
Vascular invasion has been considered as an important
prognostic factor for hepatoblastoma, although there this
issue remains under debate in the literature (12,26). In fact, in
our series, we did not detect any correlation between
survival and vascular invasion. However, a strong correla-
tion was observed between the absence of metastasis and
survival, and the patients submitted for transplantation had
poorer survival outcomes than those who underwent liver
resection. Among the 7 patients who underwent a liver
transplantation, 4 are alive and free of disease. All of these
patients had tumors in the four sectors of the liver, which
precluded liver resection; thus, total hepatectomy with
a liver transplant was the only treatment option.
Liver transplantation for primary malignant hepatic
tumors has been reported to have an incidence of approxi-
mately 2% of all pediatric transplantations (27). In fact, in our
series of 590 children submitted for liver transplantation,
7 (1.19%) had hepatoblastoma. We prefer to perform these
transplants using grafts obtained from a living related donor
due to the scarcity of cadaveric donors and the large number
of patients on the waiting list for a liver transplant.
In conclusion, our current report demonstrates that multi-
disciplinary treatment of children with hepatoblastoma is
becoming more successful, with excellent survival rates. This
mode of treatment includes the use of tumor-specific
chemotherapy, adequate planning of surgical treatment to
ensure the removal of the entire tumor via partial resection of
the liver or, if necessary, total removal of the liver and
immediate liver transplantation (using tissue from living or
deceased donors).
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Figure 2 - CT scan of a patient with hepatoblastoma in the right hepatic lobe before (a) and after (b) chemotherapy. The tumor size
decreased, and the patient underwent right hepatectomy with surgical margins that were free of tumor cells.
391
CLINICS 2015;70(6):387-392 Outcomes for children with hepatoblastoma
Tannuri AC et al.
’ REFERENCES
1. Zhang Y, Zhang WL, Huang DS, Hong L, Wang YZ, Zhu X, et al.
Clinical effectiveness of multimodality treatment on advanced
pediatric hepatoblastoma. Eur Rev Med Pharmacol Sci. 2014;18(7):
1018–26.
2. Goedeke J, Haeberle B, Schmid I, Von Schweinitz D. AFP negative
cystic liver lesion in a child should let one think of hepatoblastoma.
J Pediatr Hematol Oncol. 2011;33(6):e245–7, http://dx.doi.org/10.1097/
MPH.0b013e3181f466ec.
3. Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, et al.
Pretreatment prognostic factors for children with hepatoblastoma-- results
from the International Society of Paediatric Oncology (SIOP) study SIO-
PEL 1. Eur J Cancer. 2000;36(11):1418–25, http://dx.doi.org/10.1016/
S0959-8049(00)00074-5.
4. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A.
Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a
Pediatric Oncology Group study. J Clin Oncol. 1993;11(1):96–9.
5. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B,
et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepa-
toblastoma. N Engl J Med. 2009; 361:1662–70, http://dx.doi.org/10.1056/
NEJMoa0810613.
6. Browne M, Sher D, Grant D, Deluca E, Alonso E, Whitington PF, et al.
Survival after liver transplantation for hepatoblastoma: a 2-center
experience. J Pediatr Surg. 2008;43(11):1973–81, http://dx.doi.org/
10.1016/j.jpedsurg.2008.05.031.
7. Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC.
Hepatoblastoma state of the art: pre-treatment extent of disease,
surgical resection guidelines and the role of liver transplantation.
Curr Opin Pediatr. 2014;26(1):29–36, http://dx.doi.org/10.1097/MOP.
0000000000000042.
8. Schnater JM, Aronson DC, Plaschkes J, Perilongo G, Brown J, Otte JB,
et al. Surgical view of the treatment of patients with hepatoblastoma:
results from the first prospective trial of the International Society of
Pediatric Oncology Liver Tumor Study Group. Cancer. 2002;94(4):1111–20,
http://dx.doi.org/10.1002/(ISSN)1097-0142.
9. Tannuri AC, Tannuri U, Gibelli NE, Romão RL. Surgical treatment of
hepatic tumors in children: lessons learned from liver transplantation.
J Pediatr Surg. 2009;44(11):2083–7, http://dx.doi.org/10.1016/j.jpedsurg.
2009.06.003.
10. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist. 2008;13
(7):812–20, http://dx.doi.org/10.1634/theoncologist.2008-0011.
11. Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an
update. Curr Opin Pediatr. 2014;26(3):362–9, http://dx.doi.org/10.1097/
MOP.0000000000000081.
12. Qiao GL, Li L, Cheng W, Ge J, Zhang Z, Wei Y. Predictors of survival after
resection of children with hepatoblastoma: A single Asian center experi-
ence. Eur J Surg Oncol.2014;40(11):1533–9, http://dx.doi.org/10.1016/j.
ejso.2014.07.033.
13. Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C,
et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepato-
blastoma: a successful approach--results of the first prospective study of
the International Society of Pediatric Oncology. J Clin Oncol. 2000;18
(22):3819–28.
14. Tanimura M, Matsui I, Abe J, Ikeda H, Kobayashi N, Ohira M, et al.
Increased risk of hepatoblastoma among immature children with a lower
birth weight. Cancer Res. 1998;58(14):3032–5.
15. Reynolds P Urayama KY, Von Behren J, Feusner J. Birth characteristics
and hepatoblastoma risk in young children. Cancer. 2004;100(5):1070–6,
http://dx.doi.org/10.1002/(ISSN)1097-0142.
16. Ikeda H, Matsuyama S, Tanimura M. Association between hepato-
blastoma and very low birth weight: a trend or a chance? J Pediatr.
1997;130(4):557–60, http://dx.doi.org/10.1016/S0022-3476(97)70239-7.
17. Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, et al.
Case-control study of birth characteristics and the risk of hepatoblastoma.
Cancer Epidemiol. 2013;37(4):390–5, http://dx.doi.org/10.1016/j.canep.
2013.03.004.
18. Davies JQ, de la Hall PM, Kaschula RO, Sinclair-Smith CC, Hartley P,
Rode H, et al. Hepatoblastoma--evolution of management and outcome
and significance of histology of the resected tumor. A 31-year experience
with 40 cases. J Pediatr Surg. 2004;39(9):1321–7, http://dx.doi.org/
10.1016/j.jpedsurg.2004.05.020.
19. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic
factors and staging systems in childhood hepatoblastoma. Int J Cancer.
1997;74(6):593–9, http://dx.doi.org/10.1002/(ISSN)1097-0215.
20. Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM, Mal-
ogolowkin MH. Predictive power of pretreatment prognostic factors in
children with hepatoblastoma: a report from the Children’s Oncology
Group. Pediatr Blood Cancer. 2009;53(6):1016–22, http://dx.doi.org/
10.1002/pbc.v53:6.
21. Moon SB, Shin HB, Seo JM, Lee SK. Hepatoblastoma: 15-year experience
and role of surgical treatment. J Korean Surg Soc. 2011;81(2):134–40,
http://dx.doi.org/10.4174/jkss.2011.81.2.134.
22. Ismail H, Broniszczak D, Kaliciński P, Dembowska-Bagińska B, Perek D,
Teisseyre J, et al. Changing treatment and outcome of children with
hepatoblastoma: analysis of a single center experience over the last 20
years. J Pediatr Surg. 2012;47(7):1331–9, http://dx.doi.org/10.1016/j.
jpedsurg.2011.11.073.
23. Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH,
Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk
stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28,
http://dx.doi.org/10.1097/MOP.0000000000000046.
24. Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland
JM, Haas J, et al. Complete surgical resection is curative for children with
hepatoblastoma with pure fetal histology: a report from the Children’s
Oncology Group. J Clin Oncol. 2011;29:3301–6, http://dx.doi.org/
10.1200/JCO.2010.29.3837.
25. Haas JE, Feusner J, Finegold MJ. Small cell undifferentiated histology in
hepatoblastoma may be unfavorable. Cancer. 2001; 92:3130–4, http://dx.
doi.org/10.1002/(ISSN)1097-0142.
26. Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall’Igna P, et al.
Prognostic stratification for children with hepatoblastoma: the SIOPEL
experience. Eur J Cancer. 2012;48(10):1543–9, http://dx.doi.org/10.1016/
j.ejca.2011.12.011.
27. Tannuri AC, Gibelli NE, Ricardi LR, Santos MM, Maksoud-Filho JG,
Pinho-Apezzato ML, et al. Living related donor liver transplantation in
children. Transplant Proc. 2011;43(1):161–4, http://dx.doi.org/10.1016/
j.transproceed.2010.11.013.
392
Outcomes for children with hepatoblastoma
Tannuri AC et al.
CLINICS 2015;70(6):387-392
